A pair of assessments conducted by the American Society of Hematology (ASH) have helped identify roadblocks to improving ...

UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a ...

Following the apparent elimination of a late-stage gene therapy study last week, Swiss drug juggernaut Roche has confirmed ...

The FDA is boosting a recall effort from Boston Scientific regarding batteries potentially underpowering a number of the ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

Candid Therapeutics, a new San Diego biotech bent on becoming a leader in the emerging T-cell engager space, has unwrapped ...

In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. | In ...

Fluid Biomed has raised $27 million to move forward with the development of its bioabsorbable stent designed to divert blood ...

Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...

Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...